nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—Blood calcium decreased—Varenicline—nicotine dependence	0.04	0.0808	CcSEcCtD
Ponatinib—Peripheral ischaemia—Varenicline—nicotine dependence	0.0249	0.0503	CcSEcCtD
Ponatinib—Musculoskeletal chest pain—Varenicline—nicotine dependence	0.0234	0.0473	CcSEcCtD
Ponatinib—Coronary artery disease—Varenicline—nicotine dependence	0.023	0.0464	CcSEcCtD
Ponatinib—Night sweats—Varenicline—nicotine dependence	0.0168	0.034	CcSEcCtD
Ponatinib—FLT3—cardiovascular system—nicotine dependence	0.0155	0.0602	CbGeAlD
Ponatinib—Platelet count decreased—Varenicline—nicotine dependence	0.0153	0.0309	CcSEcCtD
Ponatinib—FGFR3—midbrain—nicotine dependence	0.0141	0.0547	CbGeAlD
Ponatinib—FGFR4—brain—nicotine dependence	0.013	0.0504	CbGeAlD
Ponatinib—BCR—midbrain—nicotine dependence	0.0122	0.0473	CbGeAlD
Ponatinib—FGFR2—cardiovascular system—nicotine dependence	0.0118	0.0458	CbGeAlD
Ponatinib—TEK—cardiovascular system—nicotine dependence	0.0113	0.0439	CbGeAlD
Ponatinib—Dysphonia—Varenicline—nicotine dependence	0.011	0.0223	CcSEcCtD
Ponatinib—FGFR1—midbrain—nicotine dependence	0.0109	0.0421	CbGeAlD
Ponatinib—PDGFRA—cardiovascular system—nicotine dependence	0.0103	0.0398	CbGeAlD
Ponatinib—SRC—cardiovascular system—nicotine dependence	0.0101	0.039	CbGeAlD
Ponatinib—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.01	0.0203	CcSEcCtD
Ponatinib—BCR—Rho GTPase cycle—FGD1—nicotine dependence	0.01	0.0405	CbGpPWpGaD
Ponatinib—RET—midbrain—nicotine dependence	0.00973	0.0377	CbGeAlD
Ponatinib—KDR—cardiovascular system—nicotine dependence	0.00927	0.0359	CbGeAlD
Ponatinib—Musculoskeletal pain—Varenicline—nicotine dependence	0.00918	0.0186	CcSEcCtD
Ponatinib—Pulmonary embolism—Varenicline—nicotine dependence	0.00907	0.0184	CcSEcCtD
Ponatinib—LYN—brain—nicotine dependence	0.00892	0.0345	CbGeAlD
Ponatinib—FGFR3—brain—nicotine dependence	0.00887	0.0344	CbGeAlD
Ponatinib—TEK—midbrain—nicotine dependence	0.00886	0.0343	CbGeAlD
Ponatinib—Influenza like illness—Varenicline—nicotine dependence	0.00881	0.0178	CcSEcCtD
Ponatinib—Dry eye—Varenicline—nicotine dependence	0.00838	0.0169	CcSEcCtD
Ponatinib—KIT—cardiovascular system—nicotine dependence	0.00822	0.0318	CbGeAlD
Ponatinib—CYP2C8—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00795	0.0322	CbGpPWpGaD
Ponatinib—BCR—brain—nicotine dependence	0.00768	0.0297	CbGeAlD
Ponatinib—KDR—midbrain—nicotine dependence	0.00724	0.028	CbGeAlD
Ponatinib—ABL1—cardiovascular system—nicotine dependence	0.00715	0.0277	CbGeAlD
Ponatinib—Hot flush—Varenicline—nicotine dependence	0.00704	0.0142	CcSEcCtD
Ponatinib—Menopausal symptoms—Varenicline—nicotine dependence	0.00698	0.0141	CcSEcCtD
Ponatinib—Atrial fibrillation—Varenicline—nicotine dependence	0.00695	0.0141	CcSEcCtD
Ponatinib—FGFR1—brain—nicotine dependence	0.00683	0.0265	CbGeAlD
Ponatinib—Cerebrovascular accident—Varenicline—nicotine dependence	0.00672	0.0136	CcSEcCtD
Ponatinib—Lethargy—Varenicline—nicotine dependence	0.00672	0.0136	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.00659	0.0133	CcSEcCtD
Ponatinib—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00653	0.0264	CbGpPWpGaD
Ponatinib—Migraine—Varenicline—nicotine dependence	0.00648	0.0131	CcSEcCtD
Ponatinib—KIT—midbrain—nicotine dependence	0.00642	0.0249	CbGeAlD
Ponatinib—RET—brain—nicotine dependence	0.00611	0.0237	CbGeAlD
Ponatinib—Dry skin—Varenicline—nicotine dependence	0.00604	0.0122	CcSEcCtD
Ponatinib—Hypokalaemia—Varenicline—nicotine dependence	0.00599	0.0121	CcSEcCtD
Ponatinib—Breast disorder—Varenicline—nicotine dependence	0.00595	0.012	CcSEcCtD
Ponatinib—Nasopharyngitis—Varenicline—nicotine dependence	0.00589	0.0119	CcSEcCtD
Ponatinib—FGFR4—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00586	0.0237	CbGpPWpGaD
Ponatinib—FGFR2—brain—nicotine dependence	0.00581	0.0225	CbGeAlD
Ponatinib—Abdominal distension—Varenicline—nicotine dependence	0.00573	0.0116	CcSEcCtD
Ponatinib—CYP3A5—Xenobiotics—CYP2A7—nicotine dependence	0.00569	0.023	CbGpPWpGaD
Ponatinib—ABL1—midbrain—nicotine dependence	0.00559	0.0216	CbGeAlD
Ponatinib—TEK—brain—nicotine dependence	0.00557	0.0216	CbGeAlD
Ponatinib—Angina pectoris—Varenicline—nicotine dependence	0.00554	0.0112	CcSEcCtD
Ponatinib—Abdominal discomfort—Varenicline—nicotine dependence	0.00546	0.011	CcSEcCtD
Ponatinib—RET—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00537	0.0217	CbGpPWpGaD
Ponatinib—Erectile dysfunction—Varenicline—nicotine dependence	0.00524	0.0106	CcSEcCtD
Ponatinib—Hyperglycaemia—Varenicline—nicotine dependence	0.00513	0.0104	CcSEcCtD
Ponatinib—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.0051	0.0206	CbGpPWpGaD
Ponatinib—Infestation—Varenicline—nicotine dependence	0.00508	0.0103	CcSEcCtD
Ponatinib—Infestation NOS—Varenicline—nicotine dependence	0.00508	0.0103	CcSEcCtD
Ponatinib—PDGFRA—brain—nicotine dependence	0.00504	0.0195	CbGeAlD
Ponatinib—Acute coronary syndrome—Varenicline—nicotine dependence	0.005	0.0101	CcSEcCtD
Ponatinib—Myocardial infarction—Varenicline—nicotine dependence	0.00498	0.0101	CcSEcCtD
Ponatinib—Stomatitis—Varenicline—nicotine dependence	0.00495	0.01	CcSEcCtD
Ponatinib—SRC—brain—nicotine dependence	0.00495	0.0192	CbGeAlD
Ponatinib—CYP2C8—Xenobiotics—CYP2A7—nicotine dependence	0.00493	0.0199	CbGpPWpGaD
Ponatinib—Hepatobiliary disease—Varenicline—nicotine dependence	0.0048	0.00971	CcSEcCtD
Ponatinib—Epistaxis—Varenicline—nicotine dependence	0.00479	0.00968	CcSEcCtD
Ponatinib—KDR—brain—nicotine dependence	0.00455	0.0176	CbGeAlD
Ponatinib—Hypoaesthesia—Varenicline—nicotine dependence	0.00453	0.00917	CcSEcCtD
Ponatinib—Oedema peripheral—Varenicline—nicotine dependence	0.00449	0.00908	CcSEcCtD
Ponatinib—Connective tissue disorder—Varenicline—nicotine dependence	0.00448	0.00906	CcSEcCtD
Ponatinib—Visual impairment—Varenicline—nicotine dependence	0.00439	0.00888	CcSEcCtD
Ponatinib—FGFR3—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00433	0.0175	CbGpPWpGaD
Ponatinib—Eye disorder—Varenicline—nicotine dependence	0.00426	0.00861	CcSEcCtD
Ponatinib—Cardiac disorder—Varenicline—nicotine dependence	0.00423	0.00855	CcSEcCtD
Ponatinib—Angiopathy—Varenicline—nicotine dependence	0.00413	0.00836	CcSEcCtD
Ponatinib—Mediastinal disorder—Varenicline—nicotine dependence	0.00411	0.00831	CcSEcCtD
Ponatinib—Chills—Varenicline—nicotine dependence	0.00409	0.00827	CcSEcCtD
Ponatinib—Arrhythmia—Varenicline—nicotine dependence	0.00407	0.00823	CcSEcCtD
Ponatinib—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00405	0.0164	CbGpPWpGaD
Ponatinib—KIT—brain—nicotine dependence	0.00403	0.0156	CbGeAlD
Ponatinib—Mental disorder—Varenicline—nicotine dependence	0.00399	0.00807	CcSEcCtD
Ponatinib—Malnutrition—Varenicline—nicotine dependence	0.00397	0.00802	CcSEcCtD
Ponatinib—Erythema—Varenicline—nicotine dependence	0.00397	0.00802	CcSEcCtD
Ponatinib—Back pain—Varenicline—nicotine dependence	0.00384	0.00776	CcSEcCtD
Ponatinib—Muscle spasms—Varenicline—nicotine dependence	0.00381	0.00771	CcSEcCtD
Ponatinib—Vision blurred—Varenicline—nicotine dependence	0.00374	0.00756	CcSEcCtD
Ponatinib—Anaemia—Varenicline—nicotine dependence	0.00367	0.00741	CcSEcCtD
Ponatinib—FGFR4—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00365	0.0147	CbGpPWpGaD
Ponatinib—RET—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00358	0.0145	CbGpPWpGaD
Ponatinib—ABCG2—midbrain—nicotine dependence	0.00352	0.0136	CbGeAlD
Ponatinib—ABL1—brain—nicotine dependence	0.00351	0.0136	CbGeAlD
Ponatinib—FGFR4—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.0035	0.0141	CbGpPWpGaD
Ponatinib—FGFR4—Signaling by NGF—FGD1—nicotine dependence	0.00348	0.0141	CbGpPWpGaD
Ponatinib—Cough—Varenicline—nicotine dependence	0.00346	0.007	CcSEcCtD
Ponatinib—SRC—E-cadherin signaling in the nascent adherens junction—WASF2—nicotine dependence	0.00344	0.0139	CbGpPWpGaD
Ponatinib—Hypertension—Varenicline—nicotine dependence	0.00342	0.00693	CcSEcCtD
Ponatinib—Myalgia—Varenicline—nicotine dependence	0.00338	0.00683	CcSEcCtD
Ponatinib—Arthralgia—Varenicline—nicotine dependence	0.00338	0.00683	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00335	0.00678	CcSEcCtD
Ponatinib—Dry mouth—Varenicline—nicotine dependence	0.0033	0.00668	CcSEcCtD
Ponatinib—ABL1—Regulation of actin dynamics for phagocytic cup formation—WASF2—nicotine dependence	0.00327	0.0132	CbGpPWpGaD
Ponatinib—RET—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00325	0.0131	CbGpPWpGaD
Ponatinib—Oedema—Varenicline—nicotine dependence	0.00324	0.00655	CcSEcCtD
Ponatinib—Infection—Varenicline—nicotine dependence	0.00322	0.0065	CcSEcCtD
Ponatinib—Nervous system disorder—Varenicline—nicotine dependence	0.00317	0.00642	CcSEcCtD
Ponatinib—Thrombocytopenia—Varenicline—nicotine dependence	0.00317	0.00641	CcSEcCtD
Ponatinib—Skin disorder—Varenicline—nicotine dependence	0.00314	0.00636	CcSEcCtD
Ponatinib—ABL1—Regulation of actin dynamics for phagocytic cup formation—WASF1—nicotine dependence	0.00313	0.0127	CbGpPWpGaD
Ponatinib—Hyperhidrosis—Varenicline—nicotine dependence	0.00313	0.00633	CcSEcCtD
Ponatinib—KDR—VEGFA-VEGFR2 Pathway—WASF2—nicotine dependence	0.00306	0.0124	CbGpPWpGaD
Ponatinib—FGFR2—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00298	0.012	CbGpPWpGaD
Ponatinib—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00295	0.00596	CcSEcCtD
Ponatinib—KDR—VEGFA-VEGFR2 Pathway—WASF1—nicotine dependence	0.00294	0.0119	CbGpPWpGaD
Ponatinib—Insomnia—Varenicline—nicotine dependence	0.00293	0.00592	CcSEcCtD
Ponatinib—KDR—Signaling by VEGF—WASF2—nicotine dependence	0.00289	0.0117	CbGpPWpGaD
Ponatinib—Dyspnoea—Varenicline—nicotine dependence	0.00289	0.00584	CcSEcCtD
Ponatinib—Dyspepsia—Varenicline—nicotine dependence	0.00285	0.00576	CcSEcCtD
Ponatinib—Decreased appetite—Varenicline—nicotine dependence	0.00281	0.00569	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00279	0.00565	CcSEcCtD
Ponatinib—Fatigue—Varenicline—nicotine dependence	0.00279	0.00564	CcSEcCtD
Ponatinib—FGFR1—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00278	0.0112	CbGpPWpGaD
Ponatinib—KDR—Signaling by VEGF—WASF1—nicotine dependence	0.00277	0.0112	CbGpPWpGaD
Ponatinib—PDGFRA—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00277	0.0112	CbGpPWpGaD
Ponatinib—Pain—Varenicline—nicotine dependence	0.00277	0.0056	CcSEcCtD
Ponatinib—Constipation—Varenicline—nicotine dependence	0.00277	0.0056	CcSEcCtD
Ponatinib—FGFR3—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.0027	0.0109	CbGpPWpGaD
Ponatinib—Gastrointestinal pain—Varenicline—nicotine dependence	0.00265	0.00535	CcSEcCtD
Ponatinib—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00265	0.0107	CbGpPWpGaD
Ponatinib—FGFR3—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00259	0.0105	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by NGF—FGD1—nicotine dependence	0.00257	0.0104	CbGpPWpGaD
Ponatinib—Abdominal pain—Varenicline—nicotine dependence	0.00256	0.00518	CcSEcCtD
Ponatinib—Body temperature increased—Varenicline—nicotine dependence	0.00256	0.00518	CcSEcCtD
Ponatinib—LYN—Fcgamma receptor (FCGR) dependent phagocytosis—WASF2—nicotine dependence	0.00248	0.01	CbGpPWpGaD
Ponatinib—ABL1—Fcgamma receptor (FCGR) dependent phagocytosis—WASF2—nicotine dependence	0.00247	0.00996	CbGpPWpGaD
Ponatinib—LYN—Fcgamma receptor (FCGR) dependent phagocytosis—WASF1—nicotine dependence	0.00237	0.0096	CbGpPWpGaD
Ponatinib—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00236	0.00955	CbGpPWpGaD
Ponatinib—ABL1—Fcgamma receptor (FCGR) dependent phagocytosis—WASF1—nicotine dependence	0.00236	0.00955	CbGpPWpGaD
Ponatinib—CYP3A5—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00233	0.00943	CbGpPWpGaD
Ponatinib—Asthenia—Varenicline—nicotine dependence	0.00232	0.0047	CcSEcCtD
Ponatinib—Pruritus—Varenicline—nicotine dependence	0.00229	0.00463	CcSEcCtD
Ponatinib—CYP2C8—brain—nicotine dependence	0.00228	0.00882	CbGeAlD
Ponatinib—ABCB1—cardiovascular system—nicotine dependence	0.00222	0.00862	CbGeAlD
Ponatinib—Diarrhoea—Varenicline—nicotine dependence	0.00221	0.00448	CcSEcCtD
Ponatinib—ABCG2—brain—nicotine dependence	0.00221	0.00857	CbGeAlD
Ponatinib—Dizziness—Varenicline—nicotine dependence	0.00214	0.00433	CcSEcCtD
Ponatinib—Vomiting—Varenicline—nicotine dependence	0.00206	0.00416	CcSEcCtD
Ponatinib—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00205	0.00828	CbGpPWpGaD
Ponatinib—Rash—Varenicline—nicotine dependence	0.00204	0.00413	CcSEcCtD
Ponatinib—Dermatitis—Varenicline—nicotine dependence	0.00204	0.00412	CcSEcCtD
Ponatinib—Headache—Varenicline—nicotine dependence	0.00203	0.0041	CcSEcCtD
Ponatinib—CYP2C8—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00202	0.00817	CbGpPWpGaD
Ponatinib—Nausea—Varenicline—nicotine dependence	0.00192	0.00389	CcSEcCtD
Ponatinib—CYP3A5—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00192	0.00775	CbGpPWpGaD
Ponatinib—FGFR2—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00185	0.0075	CbGpPWpGaD
Ponatinib—SRC—Fcgamma receptor (FCGR) dependent phagocytosis—WASF2—nicotine dependence	0.0018	0.00726	CbGpPWpGaD
Ponatinib—FGFR2—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00178	0.00719	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by NGF—FGD1—nicotine dependence	0.00177	0.00715	CbGpPWpGaD
Ponatinib—LYN—PDGFR-beta signaling pathway—WASF2—nicotine dependence	0.00175	0.00708	CbGpPWpGaD
Ponatinib—ABL1—PDGFR-beta signaling pathway—WASF2—nicotine dependence	0.00174	0.00704	CbGpPWpGaD
Ponatinib—KIT—Signaling by NGF—FGD1—nicotine dependence	0.00174	0.00702	CbGpPWpGaD
Ponatinib—ABCB1—midbrain—nicotine dependence	0.00174	0.00673	CbGeAlD
Ponatinib—FGFR1—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00173	0.00699	CbGpPWpGaD
Ponatinib—PDGFRA—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00172	0.00697	CbGpPWpGaD
Ponatinib—SRC—Fcgamma receptor (FCGR) dependent phagocytosis—WASF1—nicotine dependence	0.00172	0.00696	CbGpPWpGaD
Ponatinib—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00168	0.00679	CbGpPWpGaD
Ponatinib—CYP2C8—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00166	0.00671	CbGpPWpGaD
Ponatinib—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00166	0.0067	CbGpPWpGaD
Ponatinib—FGFR1—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00166	0.0067	CbGpPWpGaD
Ponatinib—PDGFRA—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00165	0.00668	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by NGF—FGD1—nicotine dependence	0.00165	0.00666	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by NGF—FGD1—nicotine dependence	0.00164	0.00665	CbGpPWpGaD
Ponatinib—CYP2D6—brain—nicotine dependence	0.00152	0.00588	CbGeAlD
Ponatinib—SRC—ErbB1 downstream signaling—WASF2—nicotine dependence	0.00146	0.0059	CbGpPWpGaD
Ponatinib—SRC—VEGFA-VEGFR2 Pathway—WASF2—nicotine dependence	0.00144	0.00581	CbGpPWpGaD
Ponatinib—LCK—PDGFR-beta signaling pathway—WASF2—nicotine dependence	0.00143	0.0058	CbGpPWpGaD
Ponatinib—SRC—VEGFA-VEGFR2 Pathway—WASF1—nicotine dependence	0.00138	0.00557	CbGpPWpGaD
Ponatinib—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00136	0.00551	CbGpPWpGaD
Ponatinib—SRC—Signaling by VEGF—WASF2—nicotine dependence	0.00136	0.00549	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—TAS2R16—nicotine dependence	0.00135	0.00546	CbGpPWpGaD
Ponatinib—BCR—Disease—AKR1B10—nicotine dependence	0.00134	0.0054	CbGpPWpGaD
Ponatinib—SRC—Signaling by VEGF—WASF1—nicotine dependence	0.0013	0.00526	CbGpPWpGaD
Ponatinib—SRC—PDGFR-beta signaling pathway—WASF2—nicotine dependence	0.00127	0.00513	CbGpPWpGaD
Ponatinib—FGFR4—Innate Immune System—WASF2—nicotine dependence	0.00123	0.00499	CbGpPWpGaD
Ponatinib—LCK—Signaling by NGF—FGD1—nicotine dependence	0.00119	0.00481	CbGpPWpGaD
Ponatinib—FGFR4—Innate Immune System—WASF1—nicotine dependence	0.00118	0.00478	CbGpPWpGaD
Ponatinib—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.0011	0.00444	CbGpPWpGaD
Ponatinib—ABCB1—brain—nicotine dependence	0.00109	0.00423	CbGeAlD
Ponatinib—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00108	0.00438	CbGpPWpGaD
Ponatinib—CYP3A5—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00108	0.00436	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—FGD1—nicotine dependence	0.00106	0.00428	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—FGD1—nicotine dependence	0.00105	0.00425	CbGpPWpGaD
Ponatinib—CYP3A5—Biological oxidations—CYP2A7—nicotine dependence	0.00102	0.00411	CbGpPWpGaD
Ponatinib—CYP3A5—Metapathway biotransformation—CYP2A7—nicotine dependence	0.001	0.00406	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TAS2R16—nicotine dependence	0.000952	0.00385	CbGpPWpGaD
Ponatinib—FGFR4—Disease—AKR1B10—nicotine dependence	0.000942	0.00381	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—AKR1B10—nicotine dependence	0.000936	0.00378	CbGpPWpGaD
Ponatinib—CYP2C8—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000935	0.00378	CbGpPWpGaD
Ponatinib—FGFR3—Innate Immune System—WASF2—nicotine dependence	0.000913	0.00369	CbGpPWpGaD
Ponatinib—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000891	0.0036	CbGpPWpGaD
Ponatinib—CYP2C8—Biological oxidations—CYP2A7—nicotine dependence	0.000882	0.00356	CbGpPWpGaD
Ponatinib—FGFR3—Innate Immune System—WASF1—nicotine dependence	0.000875	0.00354	CbGpPWpGaD
Ponatinib—CYP2C8—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00087	0.00351	CbGpPWpGaD
Ponatinib—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000768	0.0031	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—FGD1—nicotine dependence	0.000747	0.00302	CbGpPWpGaD
Ponatinib—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000724	0.00293	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—WASF2—nicotine dependence	0.000719	0.00291	CbGpPWpGaD
Ponatinib—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000714	0.00289	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TAS2R16—nicotine dependence	0.000704	0.00285	CbGpPWpGaD
Ponatinib—FGFR3—Disease—AKR1B10—nicotine dependence	0.000697	0.00282	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—WASF1—nicotine dependence	0.000689	0.00279	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—AKR1B10—nicotine dependence	0.00066	0.00267	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—WASF2—nicotine dependence	0.00066	0.00267	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—WASF1—nicotine dependence	0.000632	0.00256	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—WASF2—nicotine dependence	0.000628	0.00254	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—WASF2—nicotine dependence	0.000617	0.00249	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TAS2R16—nicotine dependence	0.000613	0.00248	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—WASF1—nicotine dependence	0.000602	0.00243	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—WASF1—nicotine dependence	0.000591	0.00239	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—WASF2—nicotine dependence	0.000585	0.00237	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—WASF2—nicotine dependence	0.000584	0.00236	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—OPRM1—nicotine dependence	0.000569	0.0023	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—WASF1—nicotine dependence	0.000561	0.00227	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—WASF1—nicotine dependence	0.00056	0.00226	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—FGD1—nicotine dependence	0.000552	0.00223	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—WASF2—nicotine dependence	0.000532	0.00215	CbGpPWpGaD
Ponatinib—ABCG2—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000519	0.0021	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—WASF2—nicotine dependence	0.000515	0.00208	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—WASF2—nicotine dependence	0.000513	0.00207	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—WASF1—nicotine dependence	0.00051	0.00206	CbGpPWpGaD
Ponatinib—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000502	0.00203	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—WASF1—nicotine dependence	0.000494	0.002	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—WASF1—nicotine dependence	0.000491	0.00199	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AKR1B10—nicotine dependence	0.000488	0.00197	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TAS2R16—nicotine dependence	0.000484	0.00196	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—FGD1—nicotine dependence	0.000481	0.00195	CbGpPWpGaD
Ponatinib—FGFR2—Disease—AKR1B10—nicotine dependence	0.000479	0.00194	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TAS2R16—nicotine dependence	0.000476	0.00192	CbGpPWpGaD
Ponatinib—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000473	0.00191	CbGpPWpGaD
Ponatinib—KIT—Disease—AKR1B10—nicotine dependence	0.000471	0.0019	CbGpPWpGaD
Ponatinib—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000467	0.00189	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—WASF2—nicotine dependence	0.000465	0.00188	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TAS2R16—nicotine dependence	0.000451	0.00182	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TAS2R16—nicotine dependence	0.00045	0.00182	CbGpPWpGaD
Ponatinib—FGFR1—Disease—AKR1B10—nicotine dependence	0.000447	0.00181	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—WASF1—nicotine dependence	0.000446	0.0018	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—AKR1B10—nicotine dependence	0.000446	0.0018	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AKR1B10—nicotine dependence	0.000425	0.00172	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—WASF2—nicotine dependence	0.000422	0.00171	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—DRD2—nicotine dependence	0.000412	0.00166	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—WASF1—nicotine dependence	0.000405	0.00164	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—OPRM1—nicotine dependence	0.000401	0.00162	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TAS2R16—nicotine dependence	0.000397	0.0016	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—FGD1—nicotine dependence	0.00038	0.00154	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—WASF2—nicotine dependence	0.000374	0.00151	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—FGD1—nicotine dependence	0.000373	0.00151	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—CYP2A7—nicotine dependence	0.000368	0.00149	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—WASF2—nicotine dependence	0.000366	0.00148	CbGpPWpGaD
Ponatinib—KIT—Immune System—WASF2—nicotine dependence	0.000359	0.00145	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—WASF1—nicotine dependence	0.000358	0.00145	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—FGD1—nicotine dependence	0.000354	0.00143	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—FGD1—nicotine dependence	0.000353	0.00143	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—WASF1—nicotine dependence	0.000351	0.00142	CbGpPWpGaD
Ponatinib—KIT—Immune System—WASF1—nicotine dependence	0.000344	0.00139	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—WASF2—nicotine dependence	0.000344	0.00139	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—WASF2—nicotine dependence	0.000341	0.00138	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—WASF2—nicotine dependence	0.00034	0.00137	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKR1B10—nicotine dependence	0.000336	0.00136	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKR1B10—nicotine dependence	0.00033	0.00133	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—WASF1—nicotine dependence	0.00033	0.00133	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—WASF1—nicotine dependence	0.000327	0.00132	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—WASF1—nicotine dependence	0.000326	0.00132	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TAS2R16—nicotine dependence	0.000325	0.00132	CbGpPWpGaD
Ponatinib—LCK—Disease—AKR1B10—nicotine dependence	0.000322	0.0013	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKR1B10—nicotine dependence	0.000313	0.00126	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKR1B10—nicotine dependence	0.000312	0.00126	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—FGD1—nicotine dependence	0.000312	0.00126	CbGpPWpGaD
Ponatinib—LYN—Immune System—WASF2—nicotine dependence	0.0003	0.00121	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—WASF2—nicotine dependence	0.0003	0.00121	CbGpPWpGaD
Ponatinib—ABL1—Immune System—WASF2—nicotine dependence	0.000299	0.00121	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—OPRM1—nicotine dependence	0.000297	0.0012	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—DRD2—nicotine dependence	0.00029	0.00117	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TAS2R16—nicotine dependence	0.000288	0.00116	CbGpPWpGaD
Ponatinib—LYN—Immune System—WASF1—nicotine dependence	0.000288	0.00116	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—WASF1—nicotine dependence	0.000287	0.00116	CbGpPWpGaD
Ponatinib—ABL1—Immune System—WASF1—nicotine dependence	0.000286	0.00116	CbGpPWpGaD
Ponatinib—SRC—Disease—AKR1B10—nicotine dependence	0.000285	0.00115	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.00028	0.00113	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKR1B10—nicotine dependence	0.000275	0.00111	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—OPRM1—nicotine dependence	0.000259	0.00104	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—FGD1—nicotine dependence	0.000255	0.00103	CbGpPWpGaD
Ponatinib—LCK—Immune System—WASF2—nicotine dependence	0.000246	0.000994	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—CYP2A7—nicotine dependence	0.000243	0.000982	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—WASF2—nicotine dependence	0.000236	0.000956	CbGpPWpGaD
Ponatinib—LCK—Immune System—WASF1—nicotine dependence	0.000236	0.000953	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—WASF2—nicotine dependence	0.000232	0.000939	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—WASF1—nicotine dependence	0.000227	0.000916	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FGD1—nicotine dependence	0.000226	0.000914	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKR1B10—nicotine dependence	0.000226	0.000912	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—WASF1—nicotine dependence	0.000223	0.0009	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—WASF2—nicotine dependence	0.00022	0.000891	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—WASF2—nicotine dependence	0.00022	0.000889	CbGpPWpGaD
Ponatinib—SRC—Immune System—WASF2—nicotine dependence	0.000218	0.00088	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—DRD2—nicotine dependence	0.000215	0.000867	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—WASF1—nicotine dependence	0.000211	0.000854	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—WASF1—nicotine dependence	0.000211	0.000852	CbGpPWpGaD
Ponatinib—SRC—Immune System—WASF1—nicotine dependence	0.000209	0.000843	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—OPRM1—nicotine dependence	0.000204	0.000825	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—OPRM1—nicotine dependence	0.0002	0.00081	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKR1B10—nicotine dependence	0.0002	0.000807	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—WASF2—nicotine dependence	0.000194	0.000784	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—OPRM1—nicotine dependence	0.00019	0.000769	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—OPRM1—nicotine dependence	0.00019	0.000767	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—DRD2—nicotine dependence	0.000187	0.000755	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—WASF1—nicotine dependence	0.000186	0.000751	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CYP2A7—nicotine dependence	0.000174	0.000704	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—OPRM1—nicotine dependence	0.000167	0.000677	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—WASF2—nicotine dependence	0.000159	0.000642	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—WASF1—nicotine dependence	0.000152	0.000616	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CYP2A7—nicotine dependence	0.000151	0.000609	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—DRD2—nicotine dependence	0.000148	0.000596	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—DRD2—nicotine dependence	0.000145	0.000586	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—WASF2—nicotine dependence	0.000141	0.000569	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—DRD2—nicotine dependence	0.000138	0.000556	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—OPRM1—nicotine dependence	0.000137	0.000555	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—DRD2—nicotine dependence	0.000137	0.000555	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—WASF1—nicotine dependence	0.000135	0.000545	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP2A7—nicotine dependence	0.000131	0.000531	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000124	0.0005	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—OPRM1—nicotine dependence	0.000121	0.000491	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—DRD2—nicotine dependence	0.000121	0.000489	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—DRD2—nicotine dependence	9.92e-05	0.000401	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—DRD2—nicotine dependence	8.78e-05	0.000355	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP2A7—nicotine dependence	8.09e-05	0.000327	CbGpPWpGaD
